INmune Accounts Payable vs Other Assets Analysis
INMB Stock | USD 11.29 0.45 4.15% |
INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Accounts Payable and its Other Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
Accounts Payable vs Other Assets
Accounts Payable vs Other Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Accounts Payable account and Other Assets. At this time, the significance of the direction appears to have pay attention.
The correlation between INmune Bio's Accounts Payable and Other Assets is -0.97. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Assets in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Accounts Payable and Other Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of INmune Bio are associated (or correlated) with its Other Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Assets has no effect on the direction of Accounts Payable i.e., INmune Bio's Accounts Payable and Other Assets go up and down completely randomly.
Correlation Coefficient | -0.97 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Accounts Payable
An accounting item on the balance sheet that represents INmune Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of INmune Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Other Assets
Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.The current year's Enterprise Value is expected to grow to about 185.9 M, whereas Selling General Administrative is forecasted to decline to about 6.4 M.
2010 | 2023 | 2024 (projected) | Interest Income | 77.7K | 69.9K | 62.2K | Net Interest Income | 77.7K | 69.9K | 62.2K |
INmune Bio fundamental ratios Correlations
Click cells to compare fundamentals
INmune Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
INmune Bio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 41.6M | |
Total Current Liabilities | 700.4K | 1.8M | 4.4M | 10.9M | 18.5M | 19.4M | |
Total Stockholder Equity | 23.6M | 38.8M | 80.2M | 60.1M | 38.1M | 33.6M | |
Net Tangible Assets | 7.1M | 22.2M | 63.7M | 43.6M | 50.1M | 52.6M | |
Retained Earnings | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (121.0M) | (115.0M) | |
Accounts Payable | 692.1K | 1.6M | 3.8M | 5.2M | 7.9M | 8.3M | |
Cash | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
Cash And Short Term Investments | 7.0M | 22.0M | 74.8M | 52.2M | 35.8M | 23.6M | |
Capital Surpluse | 44.8M | 72.1M | 143.9M | 151.8M | 174.6M | 183.3M | |
Total Liab | 860.5K | 1.9M | 19.7M | 21.7M | 18.9M | 19.8M | |
Total Current Assets | 7.8M | 24.0M | 82.6M | 64.7M | 39.9M | 27.2M | |
Common Stock | 8.7K | 10.8K | 13.5K | 18K | 817K | 857.9K | |
Net Debt | (6.8M) | (21.8M) | (59.6M) | (36.8M) | (25.4M) | (26.7M) | |
Non Current Assets Total | 16.7M | 16.7M | 17.3M | 17.1M | 17.1M | 16.2M | |
Net Receivables | 645.4K | 1.8M | 5.5M | 8.5M | 2.4M | 2.8M | |
Common Stock Total Equity | 8.7K | 10.8K | 13.5K | 18K | 20.7K | 12.9K | |
Common Stock Shares Outstanding | 10.3M | 12.0M | 16.1M | 17.9M | 18.0M | 14.8M | |
Liabilities And Stockholders Equity | 24.5M | 40.7M | 99.9M | 81.8M | 57.0M | 46.8M | |
Non Current Liabilities Total | 160.2K | 126.3K | 15.4M | 10.8M | 397.0K | 377.1K | |
Other Current Assets | 769.3M | 2.0B | 7.8M | 4.0M | 1.7M | 1.6M | |
Other Stockholder Equity | 44.9M | 72.1M | 143.9M | 151.8M | 158.3M | 85.3M | |
Accumulated Other Comprehensive Income | (8.5K) | 10.7K | 1K | (699K) | (799K) | (759.1K) | |
Net Invested Capital | 23.6M | 38.8M | 94.7M | 74.8M | 48.1M | 49.4M | |
Net Working Capital | 7.1M | 22.2M | 78.2M | 53.8M | 21.5M | 29.0M | |
Retained Earnings Total Equity | (21.3M) | (33.4M) | (63.7M) | (91.0M) | (81.9M) | (77.8M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
CEOs Directory Screen CEOs from public companies around the world | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.